

PHARMACEUTICAL 2020



RealRate

ARROWHEAD PHARMACEUTICALS Of arrowhead INC. Rank 52 of 358







The relative strengths and weaknesses of ARROWHEAD PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARROWHEAD PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 102% points. The greatest weakness of ARROWHEAD PHARMACEUTICALS INC. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 214%, being 178% points above the market average of 36%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 265,247              |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 17,064               |
| Liabilities, Current                        | 97,071               |
| Liabilities, Non-Current                    | 8,739                |
| Other Assets                                | 44,320               |
| Other Compr. Net Income                     | -370                 |
| Other Expenses                              | 174                  |
| Other Liabilities                           | 0                    |
| Other Net Income                            | 6,958                |
| Other Revenues                              | 168,796              |
| Property and Equipment                      | 23,215               |
| Research and Development                    | 81,049               |
| Selling, General and Administrative Expense | 26,556               |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 349,845              |
| Liabilities              | 105,809              |
| Expenses                 | 107,778              |
| Revenues                 | 168,796              |
| Stockholders Equity      | 244,036              |
| Net Income               | 67,975               |
| Comprehensive Net Income | 67,790               |
| Economic Capital Ratio   | 214%                 |

